Depression
07/01/2025
COMP006 Clinical Study
Many people who receive antidepressant treatment for their depression do not get an adequate response to the medicines they are taking. If someone is taking two or more antidepressants and they are failing, this is sometimes referred to as treatment-resistant depression or TRD.
The COMP006* study is looking into a new treatment approach for people with TRD using an investigational medicine given with psychological support. The study is suitable for people who have been diagnosed with major depression and are currently experiencing a recurrent or single episode of depression but that have not responded to antidepressant treatment.
You may be eligible to participate in the COMP006 study if you:
• Are 18 years of age or older
• Have ever been diagnosed with depression
• Are experiencing treatment-resistant depression, defined as trying 2 or more antidepressant medications for your depression but still experiencing symptoms of depression
• Meet additional study criteria
For details email the Center for Psychopharmaclologic Research and Treatment team at CPRTResearchOffice@umassmed.edu or call: 508-856-1882
COMP006 is STUDY00002365
(PI:ROTHSCHLD, Anthony)
*COMP006 is a three-part study which will last up to 62 weeks.
Part A: The primary aim of the study is to assess the effectiveness and safety of different doses of the investigational medication for reducing symptom severity in treatment-resistant depression (TRD), when administered with psychological support. This will be assessed in a 9-week, “blinded: part of the study, during which neither participants or study doctors will know which dose each person has received.
Part B: The length of time that the investigational medication may affect symptoms and long-term safety of the study drug, and the effectiveness and safety of re-treatment will be assessed in a 17-week single-dose, double-blind re-treatment part.
Part C: A 26-week open-label treatment part, where everyone will know what dose of the investigational medication, will be offered to participants who are eligible based on their outcome in Parts A and B.
_______________________________________________________________________
MOONLIGHT STUDY
Adults diagnosed with depression who are in a depressive episode could be eligible to participate in the MOONLIGHT-1 Research Study. This study is evaluating a once daily oral investigational medication.
You may be eligible to participate in the MOONLIGHT study if you:
• Are 18 years of age or older
• Have been diagnosed with depression
For details, contact the Center for Psychopharmacologic Research and Treatment at CPRTResearchOffice@umassmed.edu or 508-856-1882
IRB docket number STUDY00002402
(PI:ROTHSCHLD, Anthony)